Rheumatology Winter Clinical Symposium

09/28/2025

RA patients on steroids rack up higher costs. A Japan claims study links initial GC use to more healthcare use + spending. Here’s what they found:

Rheumatoid arthritis (RA) health insurance claims database study from Japan shows that RA patients initially treated with glucocorticoids (GCs) and disease-modifying antirheumatic drugs (DMARDs) experienced greater medical costs and healthcare utilization than patients not treated with GC. The date....

09/26/2025

RA and lung disease: Is there a deeper link? Multi-omics may unlock the RA-pulmonary fibrosis connection. Big questions, new answers—read more:

Rheumatoid arthritis (RA) is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear. A team from Taizhou Hospital in Zhejiang Province conducted....

09/24/2025

Go beyond the label. RWCS 2026’s 'Beyond the Package Insert' breaks down real-world use of key therapies—starting with cyclophosphamide. Don’t miss it. Register now: https://buff.ly/gpU2tnF

09/22/2025

Abatacept + MTX may cut ILD risk in RA. New pooled analysis shows lower ILD rates in treated patients. Promising signal—dig into the details:

A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD).

09/20/2025

More than just RA: New Mayo Clinic data shows multimorbidity and social factors predict more flares + lower remission rates. Read the full story:

A study from Olmstead county and the Mayo Clinic shows that multimorbidity and social factors predict higher rheumatoid arthritis (RA) flares and lower remission rates.

09/18/2025

Get real-world tips you won’t find on the label. RWCS 2026 dives deep with 'How I Do It' sessions led by top rheum experts! Learn more + register: https://buff.ly/gpU2tnF

09/16/2025

ILD doesn’t affect everyone equally. Where you live, who you are, and access to care matter. Here's why it’s time to rethink ILD care:

Interstitial lung diseases (ILDs) represent a complex spectrum of conditions that share one unifying truth: they are almost always serious, progressive, and life-altering. But for many patients, the burden of disease does not fall evenly. We are increasingly learning that where you live, who you are...

09/14/2025

Smolen unveiled new RA treatment recs at APLAR 2025. A refined consensus that reinforces treat-to-target is coming—get the highlights: https://buff.ly/ly7tpEE

The unveiling of the updated 2025 recommendations for RA treatment, presented by Josef Smolen in the plenary session on the first day of the conference, sparked attention. Although not yet formally published, these updated recommendations represent a refined consensus that simplifies decision-making...

09/12/2025

Do you have a rheumatology question or case for Dr. Cush? Record it today and you might be featured in an upcoming podcast episode!

Record a Question or Comment... Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.

09/09/2025

Stay sharp in RA, PsA & SpA care. Get the latest breakthroughs + expert insights at RWCS 2026. Don’t miss 'Year in Review: Rheumatology Advances.' Register now: https://buff.ly/gpU2tnF

08/21/2025

Smoking remains a top environmental risk factor for RA. GBD 2021 data shows its major impact on the global burden of rheumatoid arthritis over the past 20 years.

Detailed analysis of the Global Burden of Disease (GBD) 2021 database shows that to***co and smoking is one of the most significant environmental risk factors for Rheumatoid Arthritis (RA) over the last 20 years. This study utilized the Global Burden of Disease (GBD) 2021 database to analyze the bur...

08/19/2025

Big news in RA: The FDA has approved SetPoint Medical’s vagus nerve stimulator—a first-in-class neuroimmune device for patients not responding to current advanced therapies.

SetPoint Medical announced that the FDA has approved the company’s SetPoint System, a first-in-class neuroimmune modulation innovation for treatment of moderate-to-severe rheumatoid arthritis (RA) for those who are not adequately managed by—or cannot tolerate—existing advanced RA therapies, su...